WikiMD is the world's largest medical encyclopedia with
28,900 pages, 4,107,262 edits & 35,688,120 views.
Panitumumab
Information about Panitumumab
Panitumumab is a human monoclonal antibody to the epidermal growth factor (EGF) receptor, which is used in the treatment of refractory metastatic colorectal cancer.
Liver safety of Panitumumab
Panitumumab has been linked to minor serum enzyme elevations during therapy, but has not been implicated in cases of clinically apparent liver injury.
Mechanism of action of Panitumumab
Panitumumab (pan” i toom’ ue mab) is a human monoclonal IgG2 antibody to the epidermal growth factor receptor (EGFR, HER1), which is used to treat EGFR-expressing metastatic colorectal cancer. Panitumumab has been shown to induce objective responses in metastatic colorectal cancer and to improve progression free survival. Effects appear to be greater in patients with the wild type as opposed to mutant KRAS status.
FDA approval information for Panitumumab
Panitumumab was approved for use in the United States in 2006 and was the second monoclonal antibody to EGFR approved for use in metastatic colorectal cancer, the other agent being cetuximab (a chimeric mouse-human monoclonal IgG1 antibody) which has a similar profile of efficacy and safety.
Dosage and administration for Panitumumab
Panitumumab is available in liquid solution of 100, 200 and 400 mg in single dose vials (20 mg/mL) under the brand name Vectibix.
Side effects of Panitumumab
The recommended regimen is 6 mg/kg intravenously every 14 days until disease progression or unacceptable toxicity. Skin toxicity is the most common side effect, occurring in 90% of patients and being severe in 16% to 19%. Other side effects include fatigue, abdominal pain, nausea, anorexia, diarrhea, electrolyte disturbance, leukopenia and infections. Less common, but potentially severe side effects include infusion reactions, hypersensitivity reactions, severe skin toxicity, severe diarrhea and dehydration, pulmonary embolism and ocular toxicities.
Alphabetic list of antineoplastic agents - 0-9 - A1 - A2 - A3 - A4 - A5 -A6 - B - C - D - E - F - G - H - I - JK - L - M - NO - PQ - R - S - T - UVW - XYZ
Cost and Coupons - Panitumumab
- GoodRx compare cost & coupons for Panitumumab
- Find the lowest cost of Panitumumab
- Search for Coupons for Panitumumab
Reviews for Panitumumab
Learn more about Panitumumab
- Dailymed label info
- Scientific articles
- Drug portal Panitumumab
- toxicity info on Panitumumab
- FDA Panitumumab
Latest research (Pubmed)
External links
WikiMD needs you!
This WikiMD article Panitumumab is a stub.
If you are a healthcare professional familiar with the topic Panitumumab, or
A subject matter expert or authority on Panitumumab, you can help us.
About | Mission | Paid editors welcome!
| Panitumumab is part of WikiMD's Physician reviewed^ articles available 4free, 4all, 4ever! |
|---|
| Medicine: Health - Encyclopedia - Topics - Diseases - Cancer - Rare diseases - Random Page Navigation: Drugs - Wellness - Obesity - Diet - Ketogenic diet - W8MD weight loss diet - Editors: Recently Edited Pages - Alphabetical Order - Sponsors - USMLE The content on or accessible through WikiMD is for informational purposes only. WikiMD is not a substitute for professional medical advice. ^See full Disclaimers |
 Ad. Tired of being overweight?. W8MD's physician weight loss program can HELP* |
